12406 HORESHAM STREET, CARMEL, IN
Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences Enters Lease Agreement for New Office Space in Burlington, MA
Other Events
Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
To Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
News, Underwriting Agreement
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
S-1MEF